颅内肿瘤^(125)I粒子治疗并发颅内出血危险因素分析

Risk factors of intracranial hemorrhage with ^(125)I seeds for the treatment of brain tumors

目的分析颅内肿瘤^(125)I粒子治疗并发颅内出血的危险因素。方法回顾性分析青岛大学附属医院介入医学中心2013年3月至2020年11月行颅内肿瘤^(125)I粒子治疗患者的临床资料,共计234例,按照术后是否并发颅内出血将患者分为出血组和未出血组。应用二分类logistic回归分析对纳入的因素进行单因素分析,再将有意义的因素纳入多因素logistic回归分析确定颅内肿瘤^(125)I粒子治疗并发颅内出血的独立危险因素。结果234例接受^(125)I粒子治疗的颅内肿瘤患者术后并发颅内出血者共计22例,颅内出血发生率为9.4%。单因素分析显示:肿瘤类型、近1个月内抗血管生成药物治疗史可能是颅内肿瘤^(125)I粒子治疗并发颅内出血的影响因素(P<0.1)。多因素logistic回归分析显示,近1个月内抗血管生成药物治疗史是颅内肿瘤^(125)I粒子治疗并发颅内出血的独立危险因素(P<0.05)。结论近1个月内应用抗血管生成药物治疗是^(125)I粒子治疗并发颅内出血的独立危险因素,评估上述指标对^(125)I粒子治疗并发颅内出血有重要的临床意义。

Objective To analyze the risk factors of intracranial hemorrhage after implanting 125-iodine seeds for brain tumors.Methods A total of 234 patients with intracranial tumors receiving treatment of 125-iodine seeds from March,2013 to November,2020 were retrospectively analyzed.Patients were divided into bleeding group and non-bleeding group according to whether postoperative intracranial hemorrhage was reported.Univariate and multivariate analysis was performed by logistic regression to determine the independent risk factors of intracranial hemorrhage.Result A total of 22 cases(9.4%)reported postoperative intracranial hemorrhage in 234 patients treated with 125-iodine seeds.Univariate analysis showed that the type of tumor and the history of anti-angiogenic drug within one month were possible risk factors(P<0.1).Multivariate logistic regression analysis showed that anti-angiogenic drug within one month was the independent risk factor for intracranial hemorrhage(P<0.05).Conclusions The application of anti-angiogenic drugs within one month is the independent risk factor of intracranial hemorrhage with 125-iodine seeds for the treatment of brain tumors.